In Cancer TreatmentLearn More
Salarius is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options
Our technologies correct the dysregulated gene expression of cancer cells.
In certain cancers, the proteins that regulate gene expression become dysregulated. They may incorrectly turn cancer-promoting genes on and cancer-suppressing genes off, which can lead to disease development and progression. We are developing two classes of drugs that address gene dysregulation: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). We are currently in phase 1/2 trials with our TPI drug seclidemstat (SP-2577) and in IND-enabling studies with our TPD drug SP-3164. Our hope is to advance these drugs so that they can positively influence the lives of patients who have solid or hematologic cancers, such as leukemias and lymphomas.
Salarius is the recipient of a three-year $16.1 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award. Salarius has also received financial and in-kind support from the National Pediatric Cancer Foundation. We are located in the Texas Medical Center Innovation facility in Houston, Texas.